tyrosine kinase inhibitors

https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2017.00113/full Frontiers | Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor... Sensitizing mutations in the epidermal growth factor receptor (EGFR) predict response to EGFR tyrosine kinase inhibitors (TKIs) and both first and second gen... tyrosine kinase inhibitors epidermal growth factor third generation frontiers https://pubmed.ncbi.nlm.nih.gov/31202955/ Tyrosine kinase inhibitors and immune checkpoint inhibitors-induced thyroid disorders Recently, tyrosine kinase inhibitors (TKI) and immune checkpoint inhibitors (ICPIs) have emerged as new classes of anticancer therapies. Although generally... tyrosine kinase inhibitors immune checkpoint induced thyroid disorders https://pubmed.ncbi.nlm.nih.gov/40930104/ Detection of heterogeneous resistance mechanisms to tyrosine kinase inhibitors from cell-free DNA Though there has been substantial progress in the development of anti-human epidermal growth factor receptor 2 (HER2) therapies to treat HER2-positive... tyrosine kinase inhibitors https://www.techtransfer.nih.gov/patent/e-147-2010-0-us-01 C-Abl Tyrosine Kinase Inhibitors Useful For Inhibiting Filovirus Replicationc | Technology Transfer tyrosine kinase inhibitors useful for https://fse.studenttheses.ub.rug.nl/32745/ Development of PBPK models for Tyrosine Kinase Inhibitors in special patient population - Student... tyrosine kinase inhibitors https://www.crig.ugent.be/en/tags/tyrosine-kinase-inhibitors tyrosine kinase inhibitors | CRIG tyrosine kinase inhibitors https://www.techtransfer.nih.gov/patent/e-182-2019-2-us-07 RECEPTOR TYROSINE KINASE INHIBITORS FOR TREATMENT OF PROTEIN KINASE MODULATION-RESPONSIVE DISEASE... tyrosine kinase inhibitors receptor https://pubs.rsc.org/en/content/articlelanding/2012/md/c2md00317a Chimerically designed HDAC- and tyrosine kinase inhibitors. A series of erlotinib hybrids as... The regulation of chromatin structure and, therefore, transcriptional activity of histone proteins by reversible lysine acetylation is an important... tyrosine kinase inhibitors https://www.cochrane.org/evidence/CD015140_do-epidermal-growth-factor-receptor-egfr-tyrosine-kinase-inhibitors-tkis-after-lung-cancer-surgery Do epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) after lung cancer... epidermal growth factor tyrosine kinase inhibitors https://pubmed.ncbi.nlm.nih.gov/41912913/ BCR::ABL1 tyrosine kinase inhibitors induce ribosome collisions to activate ZAK-dependent ribotoxic... Ribosome collisions act as molecular sensors of cellular stress, yet their role in disease physiology remains unclear. Here, we demonstrate that inhibition of... tyrosine kinase inhibitors https://pubmed.ncbi.nlm.nih.gov/34769090/ Emerging Importance of Tyrosine Kinase Inhibitors against Cancer: Quo Vadis to Cure? GLOBOCAN 2020 estimated more than 19.3 million new cases, and about 10 million patients were deceased from cancer in 2020. Clinical manifestations showed that... tyrosine kinase inhibitors https://pubmed.ncbi.nlm.nih.gov/41162931/ BCR-ABL tyrosine kinase inhibitors associated acute kidney injury: a pharmacovigilance study based... tyrosine kinase inhibitors acute kidney injury https://pubmed.ncbi.nlm.nih.gov/41025729/ Impact of starting dose of tyrosine kinase inhibitors on outcomes following combination therapy of... The starting dose of TKIs did not significantly impact clinical outcomes following IO-TKI for RCC. These findings suggest a potential for the optimization of... tyrosine kinase inhibitors https://adisinsight.springer.com/drugsafety/803910406?error=cookies_not_supported&code=222735ba-cbc9-4883-91c1-f24610e02ea0 Protein tyrosine kinase inhibitors - AdisInsight A man with mixed-phenotype acute leukemia (MPAL) with BCR::ABL1 fusion developed relapse and subsequently died during treatment with a tyrosine kinase inhibitor protein tyrosine kinase inhibitors adisinsight https://pmc.ncbi.nlm.nih.gov/articles/PMC6993877/ Tyrosine Kinase Inhibitors (TKI) in Leukemia and Cardiovascular events - From mechanism to patient... Targeted oncology therapies have revolutionized cancer treatment over the last decade and have resulted in improved prognosis for many patients. This advance... tyrosine kinase inhibitors https://pubmed.ncbi.nlm.nih.gov/36612311/ Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cancer Seven tyrosine kinase inhibitor compounds with anti-angiogenic properties remain key drugs to treat advanced renal cell carcinoma. There is a strong rationale... therapeutic drug monitoring tyrosine kinase inhibitors https://pubmed.ncbi.nlm.nih.gov/28149764/ Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive... Osimertinib, third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), has been approved in the US and EU for the treatment of... epidermal growth factor tyrosine kinase inhibitors third generation https://adisinsight.springer.com/drugsafety/803926976?error=cookies_not_supported&code=a9b9a88e-fa9c-45d6-aa6a-148ebe7c9604 Protein tyrosine kinase inhibitors - AdisInsight Two patients with chronic myeloid leukaemia (CML) developed extramedullary blast crisis, presenting as isolated acetabular myeloid sarcoma, despite treatment protein tyrosine kinase inhibitors adisinsight https://pubmed.ncbi.nlm.nih.gov/34290828/ Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic... Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of... tyrosine kinase inhibitors https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.674748/full Frontiers | Arterial Hypertension and Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A... Background: Off-target effects in chronic myeloid leukemia (CML) patients treated with Tyrosine kinase inhibitors (TKI) are associated with cardiovascular t... tyrosine kinase inhibitors chronic myeloid leukemia arterial hypertension https://www.techtransfer.nih.gov/patent/e-200-2011-1-us-01 METHODS OF TREATING LYMPHOCYTIC LEUKEMIA USING INHIBITORS OF BRUTON'S TYROSINE KINASE | Technology... https://researchprofiles.ku.dk/en/publications/selective-tyrosine-kinase-2-inhibitors-in-inflammatory-bowel-dise/ Selective tyrosine kinase 2 inhibitors in inflammatory bowel disease - University of Copenhagen... inflammatory bowel disease tyrosine kinase https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1535444/full Frontiers | Efficacy and safety of PD-1/PD-L1 inhibitors combined with tyrosine kinase inhibitors... BackgroundThe use of immune checkpoint inhibitors (ICIs) in treating hepatocellular carcinoma (HCC) has grown significantly. However, the therapeutic benefit... efficacy and safety https://adisinsight.springer.com/drugsafety/803929909?error=cookies_not_supported&code=ebc9245d-f5c9-4b8e-97ba-371b8c18b0c5 Fms-like tyrosine kinase 3 inhibitors/Venetoclax - AdisInsight Three elderly patients [sex not stated; exact ages not stated] with relapsed or refractory FLT3-ITD-positive acute myeloid leukaemia experienced severe tyrosine kinase fms like inhibitors venetoclax https://pubmed.ncbi.nlm.nih.gov/27414975/ Ultrafast Online SPE-MS/MS Method for Quantification of 3 Tyrosine Kinase Inhibitors in Human Plasma Routine clinical practice requiring high-throughput methods for therapeutic drug monitoring of TKIs may benefit from the online SPE-MS/MS method that provides... https://pubchem.ncbi.nlm.nih.gov/bioassay/1795100 AID 1795100 - Bruton's Tyrosine Kinase (BTK) Inhibition Assay from US Patent US9556147: "Inhibitors... BioAssay record AID 1795100 submitted by BindingDB: Bruton's Tyrosine Kinase (BTK) Inhibition Assay from US Patent US9556147: https://profiles.wustl.edu/en/publications/tyrosine-kinase-inhibitors-prevent-cytokine-induced-expression-of/fingerprints/ Tyrosine kinase inhibitors prevent cytokine-induced expression of iNOS and COX-2 by human islets -... https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2023.1217147/full Frontiers | Janus kinase inhibitors in systemic lupus erythematosus: implications for tyrosine... Aberrant activation of the Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathway is common in systemic lupus erythematosus (... systemic lupus erythematosus kinase inhibitors frontiers janus https://research.wur.nl/en/publications/impact-of-tyrosine-kinase-inhibitors-on-glucose-control-and-insul/ Impact of tyrosine kinase inhibitors on glucose control and insulin regulation in patients with... https://oru.diva-portal.org/smash/record.jsf?pid=diva2:1371744 Varying effects of tyrosine kinase inhibitors on platelet function : A need for individualized CML... https://pubchem.ncbi.nlm.nih.gov/bioassay/1805145 AID 1805145 - Inhibition Assay from US Patent US11554118: "Bruton's tyrosine kinase inhibitors" -... BioAssay record AID 1805145 submitted by BindingDB: Inhibition Assay from US Patent US11554118: https://publikationen.uni-tuebingen.de/xmlui/handle/10900/129844 Combination of immune checkpoint inhibitors and tyrosine kinase inhibitors for the treatment of... immune checkpoint inhibitors tyrosine kinase for the combination https://pubchem.ncbi.nlm.nih.gov/bioassay/1795552 AID 1795552 - Kinase Inhibition Assay from Article 10.1021/jm970366v: "Tyrosine kinase inhibitors.... BioAssay record AID 1795552 submitted by BindingDB: Kinase Inhibition Assay from Article 10.1021/jm970366v: https://videocast.nih.gov/watch/9de1ac22-d5db-11f0-9cf9-12c45c580ad9 NIH VideoCast - TRACO: Introduction and Lung Tyrosine Kinase Inhibitors tyrosine kinase nih videocast traco introduction https://pubmed.ncbi.nlm.nih.gov/25202262/ Tyrosine Kinase Inhibitors in EGFR-Mutated Large-Cell Neuroendocrine Carcinoma of the Lung? A Case... Large-cell neuroendocrine carcinoma (LCNEC) of the lung is a high-grade carcinoma belonging to the neuroendocrine tumors of the lung and is different from... https://pubmed.ncbi.nlm.nih.gov/33322337/ Differential Effects of IGF-1R Small Molecule Tyrosine Kinase Inhibitors BMS-754807 and OSI-906 on... We have determined the effects of the IGF-1R tyrosine kinase inhibitors BMS-754807 (BMS) and OSI-906 (OSI) on cell proliferation and cell-cycle phase... https://www.mdpi.com/2305-6304/13/3/210 Safety Profile and Hepatotoxicity of Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: A... Anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK-TKIs) have become first-line therapies for advanced non-small cell lung cancer (NSCLC) with ALK... safety profile hepatotoxicity

Robuta